A5079814358- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Bone health and osteoporosis research
- Cancer Risks and Factors
- Bone health and treatments
- Cancer Treatment and Pharmacology
- Nutritional Studies and Diet
- Breast Cancer Treatment Studies
- Nutrition and Health in Aging
- Cancer-related cognitive impairment studies
- Medical Imaging Techniques and Applications
- COVID-19 and healthcare impacts
- Occupational and environmental lung diseases
- Advanced Chemical Sensor Technologies
- Olfactory and Sensory Function Studies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Biochemical Analysis and Sensing Techniques
- Pleural and Pulmonary Diseases
- Infection Control and Ventilation
- Brain Metastases and Treatment
- Gastrointestinal Tumor Research and Treatment
- Facial Nerve Paralysis Treatment and Research
- Ear and Head Tumors
- Soft tissue tumor case studies
- Sleep and Wakefulness Research
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
2020-2024
University of Brescia
2020-2024
University of Milano-Bicocca
2020
Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 evaluated, HER2-low was independently associated significantly worse PFS and OS when compared HER2-0 status. Based on our findings, could become a new biomarker this clinical setting.
Background . Trastuzumab emtansine (T-DM1), sacituzumab govitecan (SG), and trastuzumab deruxtecan (T-DXd) are three ADCs approved for the treatment of metastatic breast cancer (MBC). Since gastrointestinal toxicities have been commonly observed with these drugs in clinical trials, a pooled analysis evaluating adverse events (AEs) patients MBC treated trials was performed. Methods PubMed, Embase, Cochrane Library were searched from inception until May 2023 phase II III reporting frequency...
Post-traumatic pseudoaneurysm of the superficial temporal artery (STA) represents a rare clinical condition that usually follows blunt trauma; it manifests as pulsatile swelling along course in fronto-temporal site. In this paper, Authors present case post - traumatic right STA developed 2 months after suffering contusive trauma With reference to literature data, we also reviewed pathophysiology involved formation and approach diagnose management type injury. A thorough examination with...
Importance Women with early breast cancer (EBC) exposed to aromatase inhibitors (AIs) may experience fragility fractures despite treatment bone-active drugs. Risk factors for in patients receiving AIs and denosumab have not been explored date. Objectives To evaluate whether an association exists between dual x-ray absorptiometry (DXA)–measured fat body mass (FBM) vertebral fracture (VF) progression postmenopausal women EBC undergoing adjuvant therapy combination examine VF was associated...
ABSTRACT Aromatase inhibitors (AIs) induce depletion of estrogen levels, causing bone loss and increased fracture risk in women with breast cancer. High‐fat body mass (FBM) emerged as an independent factor associated the prevalence morphometric vertebral fractures (VFs) patients undergoing AIs. We explored role lean (LBM) interaction LBM FBM predicting occurrence VFs postmenopausal who were either AI‐naïve or AI‐treated. A total 684 consecutive cancer enrolled this cross‐sectional study....
Triple-negative breast cancer (TNBC) is an aggressive subtype, owing to its high metastatic potential: Patients who develop brain metastases (BMs) have a poor prognosis due the lack of effective systemic treatments. Surgery and radiation therapy are valid options, while pharmacotherapy still relies on chemotherapy, which has limited efficacy. Among new treatment strategies available, antibody-drug conjugate (ADC) sacituzumab govitecan shown encouraging activity in TNBC, even presence BMs.A...
Abstract Change in eating habits early breast cancer (EBC) patients during chemotherapy has been poorly studied the literature. The primary aim of this study was to prospectively evaluate food preferences and weight change EBC before after adjuvant chemotherapy. From April 2014 June 2018, 205 underwent a dietary assessment according following timeline: baseline evaluation (one week starting chemotherapy, T0); first follow-up (approximately 2–3 months T1); final end, T2). A statistically...
Bone mineral density (BMD) lacks sensitivity in individual fracture risk assessment early breast cancer (EBC) patients treated with aromatase inhibitors (AIs). New dual-energy X-ray absorptiometry (DXA) based factors are needed.Trabecular bone score (TBS), strain index (BSI) and DXA parameters of geometry were evaluated postmenopausal women diagnosed EBC. The aim was to explore their association morphometric vertebral fractures (VFs). Subjects categorized 3 groups order evaluate the impact...
Abstract Purpose We aimed to investigate the role of a lifestyle intervention and clinical therapeutic factors for preventing weight gain in early breast cancer (BC) patients from one week before 12 months after chemotherapy. Methods Dietary assessments were conducted by trained dietician using food-frequency questionnaire at each assessment. Total energy, macronutrients intakes, physical activity estimated Mediterranean Diet Score (MDS) adherence diet was calculated. At follow-up visit,...
Whether adjuvant therapy with aromatase inhibitors (AIs) causes sleep disturbances or not in postmenopausal women early breast cancer (EBC) is still a controversial issue.Between March 2014 and November 2017, validated questionnaires for assessing insomnia, anxiety, depression, quality of life (QoL) restless legs syndrome (RLS) were administered to 160 EBC patients at baseline after 3, 6, 12, 24 months AI therapy.AI significantly decreased the patients' QoL, but did influence anxiety...
Regorafenib is an oral multi-targeted tyrosine kinase inhibitor (TKI) indicated for the treatment of various tumor types, including metastatic gastrointestinal stromal tumors (GIST), as a third-line systemic therapy. Erythrocytosis, which characterized by increase in erythrocyte count, hemoglobin, and hematocrit levels, has been described side effect some antiangiogenic TKIs but never associated with regorafenib administration.
Abstract Introduction: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) are the standard first-line treatment for patients hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (HR+/HER2- aBC). HER2-low BC, which is defined by an IHC score HER2 of 1+ or 2+ negative ISH assay, accounts more than half all HR+/HER2- aBC cases, and it associated remarkable clinical benefit from novel anti-HER2...
Abstract Purpose Triple-negative breast cancer (TNBC) represents a subtype of which lacks the expression oestrogen receptor (ER), progesterone (PR) and human epidermal growth factor receptor-2 (HER2): TNBC accounts for approximately 20% newly diagnosed cancers is associated with younger age at diagnosis, greater recurrence risk shorter survival time. Therapeutic options are very scarce. Aim present analysis to provide further insights into clinical activity metronomic chemotherapy (mCHT), in...
Abstract Background The DigniCap System is an effective scalp cooling device for the prevention of chemotherapy‐induced alopecia in early breast cancer patients. Aim This prospective study was designed to confirm efficacy and tolerability device, explore potential factors associated with its collect data on patient perceptions satisfaction. Methods Between January 2016 June 2018, 163 patients eligible adjuvant chemotherapy were enrolled. Hair loss assessed using Dean scale, where a score 0–2...
Cyclin-Dependent Kinase 4/6 inhibitors (CDK4/6i) combined with Endocrine Therapy (ET) are the standard treatment for patients Hormone Receptor-positive/HER2-negative advanced breast cancer (HR+/HER2- aBC).
Chemotherapy-induced taste alterations (TAs) affect approximately 53-84% of breast cancer patients with significant consequences on flavor perception, possibly leading to food aversion and changes in daily dietary habits. The aim this study was investigate the relationship between TAs habits body weight among early (EBC) undergoing adjuvant chemotherapy.TAs were prospectively evaluated 182 EBC from April 2014 June 2018. TAs, habits, collected by a trained dietician. classified into different...
A 50-year-old man with recently diagnosed lung cancer presented shortness of breath and a cough. Water-soluble contrast esophagography (shown in video) revealed bronchoesophageal fistula.